Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up.
CDG
Cirrhosis
Glycosylation
Liver fibrosis
Liver injury
Phenotyping
Phosphomannomutase-2
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
14
09
2020
accepted:
27
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
The congenital disorders of glycosylation (CDG) are a heterogeneous group of rare metabolic diseases with multi-system involvement. The liver phenotype of CDG varies not only according to the specific disorder, but also from patient to patient. In this study, we sought to identify common patterns of liver injury among patients with a broad spectrum of CDG, and to provide recommendations for follow-up in clinical practice. Patients were enrolled in the Frontiers in Congenital Disorders of Glycosylation natural history study. We analyzed clinical history, molecular genetics, serum markers of liver injury, liver ultrasonography and transient elastography, liver histopathology (when available), and clinical scores of 39 patients with 16 different CDG types (PMM2-CDG, n = 19), with a median age of 7 years (range: 10 months to 65 years). For patients with disorders which are treatable by specific interventions, we have added a description of liver parameters on treatment. Our principal findings are (1) there is a clear pattern in the evolution of the hepatocellular injury markers alanine aminotransferase and aspartate aminotransferase according to age, especially in PMM2-CDG patients but also in other CDG-I, and that the cholangiocellular injury marker gamma-glutamyltransferase is not elevated in most patients, pointing to an exclusive hepatocellular origin of injury; (2) there is a dissociation between liver ultrasound and transient elastography regarding signs of liver fibrosis; (3) histopathological findings in liver tissue of PMM2-CDG patients include cytoplasmic glycogen deposits; and (4) most CDG types show more than one type of liver injury. Based on these findings, we recommend that all CDG patients have regular systematic, comprehensive screening for liver disease, including physical examination (for hepatomegaly and signs of liver failure), laboratory tests (serum alanine aminotransferase and aspartate aminotransferase), liver ultrasound (for steatosis and liver tumors), and liver elastography (for fibrosis).
Sections du résumé
BACKGROUND
The congenital disorders of glycosylation (CDG) are a heterogeneous group of rare metabolic diseases with multi-system involvement. The liver phenotype of CDG varies not only according to the specific disorder, but also from patient to patient. In this study, we sought to identify common patterns of liver injury among patients with a broad spectrum of CDG, and to provide recommendations for follow-up in clinical practice.
METHODS
Patients were enrolled in the Frontiers in Congenital Disorders of Glycosylation natural history study. We analyzed clinical history, molecular genetics, serum markers of liver injury, liver ultrasonography and transient elastography, liver histopathology (when available), and clinical scores of 39 patients with 16 different CDG types (PMM2-CDG, n = 19), with a median age of 7 years (range: 10 months to 65 years). For patients with disorders which are treatable by specific interventions, we have added a description of liver parameters on treatment.
RESULTS
Our principal findings are (1) there is a clear pattern in the evolution of the hepatocellular injury markers alanine aminotransferase and aspartate aminotransferase according to age, especially in PMM2-CDG patients but also in other CDG-I, and that the cholangiocellular injury marker gamma-glutamyltransferase is not elevated in most patients, pointing to an exclusive hepatocellular origin of injury; (2) there is a dissociation between liver ultrasound and transient elastography regarding signs of liver fibrosis; (3) histopathological findings in liver tissue of PMM2-CDG patients include cytoplasmic glycogen deposits; and (4) most CDG types show more than one type of liver injury.
CONCLUSIONS
Based on these findings, we recommend that all CDG patients have regular systematic, comprehensive screening for liver disease, including physical examination (for hepatomegaly and signs of liver failure), laboratory tests (serum alanine aminotransferase and aspartate aminotransferase), liver ultrasound (for steatosis and liver tumors), and liver elastography (for fibrosis).
Identifiants
pubmed: 33413482
doi: 10.1186/s13023-020-01630-2
pii: 10.1186/s13023-020-01630-2
pmc: PMC7788939
doi:
Substances chimiques
Phosphotransferases (Phosphomutases)
EC 5.4.2.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : NINDS NIH HHS
ID : U54 NS115198
Pays : United States
Références
Orphanet J Rare Dis. 2018 Jan 10;13(1):4
pubmed: 29321044
Int J Oncol. 1997 Feb;10(2):261-8
pubmed: 21533371
Mol Genet Metab. 2008 Jan;93(1):40-3
pubmed: 17945525
Genet Med. 2020 Jun;22(6):1102-1107
pubmed: 32103184
Front Cell Dev Biol. 2019 Aug 13;7:157
pubmed: 31457009
Hepatology. 2020 Mar 7;:
pubmed: 32145091
Am J Hum Genet. 2016 Feb 4;98(2):310-21
pubmed: 26833332
J Proteome Res. 2014 Mar 7;13(3):1713-21
pubmed: 24495048
Am J Hum Genet. 2012 Jul 13;91(1):15-26
pubmed: 22683087
J Inherit Metab Dis. 2016 Sep;39(5):713-723
pubmed: 27287710
J Inherit Metab Dis. 2019 May;42(3):553-564
pubmed: 30746764
Biochim Biophys Acta. 2009 Sep;1792(9):835-40
pubmed: 19339218
J Inherit Metab Dis. 2019 Jan;42(1):5-28
pubmed: 30740725
Am J Hum Genet. 2016 Feb 4;98(2):322-30
pubmed: 26833330
Mol Genet Metab. 2019 Dec;128(4):409-414
pubmed: 31481313
Genet Med. 2017 Nov;19(11):1226-1235
pubmed: 28617415
Mol Genet Metab. 2019 Jun;127(2):117-121
pubmed: 31005404
Hum Mol Genet. 2012 Oct 1;21(19):4151-61
pubmed: 22492991
Genet Med. 2018 Feb;20(2):259-268
pubmed: 28749473
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1375-1386
pubmed: 28323990
J Inherit Metab Dis. 2015 Sep;38(5):931-40
pubmed: 25778940
Clin Genet. 2019 May;95(5):615-626
pubmed: 30653653
Haematologica. 2019 Feb;104(2):e79-e82
pubmed: 30545931
Diagn Interv Imaging. 2013 May;94(5):515-34
pubmed: 23623211
Genet Med. 2020 Feb;22(2):268-279
pubmed: 31534212
Genet Med. 2019 May;21(5):1181-1188
pubmed: 30293989
J Inherit Metab Dis. 2017 Mar;40(2):195-207
pubmed: 28108845
J Inherit Metab Dis. 2011 Aug;34(4):923-7
pubmed: 21541726
Am J Hum Genet. 2019 May 2;104(5):835-846
pubmed: 30982613
Eur J Med Genet. 2018 Nov;61(11):643-663
pubmed: 29079546
Int J Mol Sci. 2018 Apr 27;19(5):
pubmed: 29702557
Am J Hum Genet. 2012 Feb 10;90(2):363-8
pubmed: 22305527
Clin Chim Acta. 2014 Apr 20;431:15-8
pubmed: 24508628
Pediatrics. 2014 Jul;134(1):e279-83
pubmed: 24982104
Hum Mutat. 2019 Jul;40(7):908-925
pubmed: 30817854
Mol Genet Metab. 2018 Jul;124(3):228-235
pubmed: 29759592
J Inherit Metab Dis. 2020 Jul;43(4):671-693
pubmed: 32266963
Mol Genet Metab. 2019 Jan;126(1):1-5
pubmed: 30454869
Hum Mol Genet. 2014 Jun 1;23(11):2880-7
pubmed: 24403049
Orphanet J Rare Dis. 2016 Jun 24;11(1):84
pubmed: 27343064
Nutrients. 2017 Nov 07;9(11):
pubmed: 29112118